NEK9 and CDK16 were chosen for further study based upon their potent inhibition by dabrafenib in in vitro kinase assays, and by preliminary siRNA experiments in which their silencing inhibited the growth of NRAS‐mutant melanoma cells. Here, NEK9 is linked to melanoma.